Table 3 Effect of montelukast on spirometric values
From: Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast
Baseline | 4 weeks | 8 weeks | |
|---|---|---|---|
FEV1% (montelukast) | 81.2 ± 15.8 | 77.5 ± 16.1 | 77.3 ± 17.7 |
FEV1% (placebo) | 76.6 ± 16.4 | 75.2 ± 17 | |
FEV1/FVC (montelukast) | 0.74 ± 0.1 | 0.75 ± 0.1 | 0.74 ± 0.1 |
FEV1/FVC (placebo) | 0.74 ± 0.1 | 0.74 ± 0.1 | |
FEF25-75% (montelukast) | 78.2 ± 31.5 | 75.5 ± 32.2 | 75.4 ± 35 |
FEF25-75% (placebo) | 72.7 ± 29 | 73.1 ± 30.8 |